These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12127872)

  • 1. Inhibitors of integrins.
    Tucker GC
    Curr Opin Pharmacol; 2002 Aug; 2(4):394-402. PubMed ID: 12127872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C; Dormond O; Mariotti A
    Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrins as therapeutic targets: lessons and opportunities.
    Cox D; Brennan M; Moran N
    Nat Rev Drug Discov; 2010 Oct; 9(10):804-20. PubMed ID: 20885411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting integrins for the control of tumour angiogenesis.
    Akalu A; Cretu A; Brooks PC
    Expert Opin Investig Drugs; 2005 Dec; 14(12):1475-86. PubMed ID: 16307488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.
    Rüegg C; Alghisi GC
    Recent Results Cancer Res; 2010; 180():83-101. PubMed ID: 20033379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
    Rüegg C; Dormond O; Foletti A
    Endothelium; 2002; 9(3):151-60. PubMed ID: 12380640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha v integrin inhibitors and cancer therapy.
    Tucker GC
    Curr Opin Investig Drugs; 2003 Jun; 4(6):722-31. PubMed ID: 12901232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug inhibition of angiogenesis.
    Madhusudan S; Harris AL
    Curr Opin Pharmacol; 2002 Aug; 2(4):403-14. PubMed ID: 12127873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function and antagonism of beta3 integrins in the development of cancer therapy.
    Sheldrake HM; Patterson LH
    Curr Cancer Drug Targets; 2009 Jun; 9(4):519-40. PubMed ID: 19519320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.
    Kumar CC
    Curr Drug Targets; 2003 Feb; 4(2):123-31. PubMed ID: 12558065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of β3-integrins in tumor angiogenesis: context is everything.
    Robinson SD; Hodivala-Dilke KM
    Curr Opin Cell Biol; 2011 Oct; 23(5):630-7. PubMed ID: 21565482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of integrins.
    Stupack DG
    Oncology (Williston Park); 2007 Aug; 21(9 Suppl 3):6-12. PubMed ID: 17927025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D; Manzoni L; Corno C; Perego P
    Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.
    Reynolds LE; Wyder L; Lively JC; Taverna D; Robinson SD; Huang X; Sheppard D; Hynes RO; Hodivala-Dilke KM
    Nat Med; 2002 Jan; 8(1):27-34. PubMed ID: 11786903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
    Sheldrake HM; Patterson LH
    J Med Chem; 2014 Aug; 57(15):6301-15. PubMed ID: 24568695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.
    Alghisi GC; Rüegg C
    Endothelium; 2006; 13(2):113-35. PubMed ID: 16728329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas.
    Bello L; Zhang J; Nikas DC; Strasser JF; Villani RM; Cheresh DA; Carroll RS; Black PM
    Neurosurgery; 2000 Nov; 47(5):1185-95. PubMed ID: 11063113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of alpha v integrins during angiogenesis.
    Eliceiri BP; Cheresh DA
    Cancer J; 2000 May; 6 Suppl 3():S245-9. PubMed ID: 10874494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.